Banking on cord blood stem cells

Nature Reviews Cancer

Volumn 8, Issue 10, 2008, Pages 823-

  Sullivan, Michael J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD BANK; BRAIN ISCHEMIA; BRAIN TUMOR; CEREBRAL PALSY; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; CRYOPRESERVATION; EPENDYMOMA; EWING SARCOMA; GERM CELL TUMOR; GLIOBLASTOMA; GLIOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; MEDICAL INFORMATION; MEDICAL TECHNOLOGY; MEDULLOBLASTOMA; NEPHROBLASTOMA; NEUROIMAGING; PATIENT DECISION MAKING; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SARCOMA; TREATMENT INDICATION; UMBILICAL CORD BLOOD;

EID: 52649083626     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2418-c3     Document Type: Letter

References (25)

1. Sullivan, M. J. Banking on cord blood stem cells. Nature Rev. Cancer 8, 555-563 (2008).
2. Nietfeld, J. J. Opinions regarding cord blood use need an update. Nature Rev. Cancer 24 Sep 2008 (doi:10.1038/nrg2418-c1).
3. Harris, D. T. Cord blood stem cells: worth the investment. Nature Rev. Cancer 24 Sep 2008 (doi:10.1038/nrg2418-c2).
4. Nietfeld, J. J., Pasquini, M. C., Logan, B. R., Verter, F. & Horowitz, M. M. Lifetime probabilities of hematopoietic stem cell transplantation in the US. Biol. Blood Marrow Transplant. 14, 316-322 (2008).
5. Nietfeld, J. J., Pasquini, M. P., Logan, B. R., Verter, F. & Horowitz, M. M. On the probability of using cord blood. Biol. Blood Marrow Transplant.14, 724-725 (2008).
6. Ballen, K. K., Barker, J. N., Stewart, S. K., Greene, M. F. & Lane TA; American Society of Blood and Marrow Transplantation. Collection and preservation of cord blood for personal use. Biol. Blood Marrow Transplant. 14, 356-363 (2008).
7. Durando, X. et al. High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients. Bone Marrow Transplant. 31, 559-564 (2003).
8. Jacques-Olivier, B. et al. Does high-dose carmustine increase overall survival in supratentorial high-grade malignant glioma? An EBMT retrospective study. Int. J. Cancer 120, 1782-1786 (2007).
9. Zacharoulis, S. et al. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr. Blood Cancer 49, 34-40 (2007).
10. Thorarinsdottir, H. K. et al. Outcome for children < 4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue. Pediatr. Blood Cancer 48, 278-284 (2007).
11. Guruangan, S. et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J. Clin. Oncol. 16, 2486-2493 (1998).
12. Gururangan, S. et al. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. J. Clin. Oncol. 21, 2187-2191 (2003).
13. Yamada, K. et al. High-dose chemotherapy and autologous peripheral blood stem cell transfusion for adult and adolescent patients with small round cell sarcomas. Bone Marrow Transplant. 39, 471-476 (2007).
14. Ek, E. T. H. & Choong, P. F. M. The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas. Exp. Rev. Anticancer Ther. 6, 225-237 (2006).
15. Meyers, P. A. High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr. Opin. Oncol. 16, 120-125 (2004).
16. Schlemmer, M. et al. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. Oncology 71, 32-39 (2006).
17. Boulad, F. et al. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma. J. Clin. Oncol. 16, 1697-1706 (1998).
18. Koscielniak, E. et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant. 19, 227-231 (1997).
19. Maherali, N. et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 1, 55-70 (2007).
20. Park, I. H. et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451, 141-146 (2008).
21. Wernig, M. et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state.[see comment]. Nature 448, 318-324 (2007).
22. Yamanaka, S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 1, 39-49 (2007).
23. Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920 (2007).
24. Müller, F.-J. et al. Regulatory networks define phenotypic classes of human stem cell lines. Nature 27 Aug 2008 (doi:10.1038/ nature07213).
25. Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J. & Melton D. A. In vivo reprogramming of adult pancreatic exocrine cells to β-cells. Nature 27 Aug 2008 (doi:10.1038/nature07314).